92 related articles for article (PubMed ID: 8687125)
41. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
[TBL] [Abstract][Full Text] [Related]
42. Exposure of Sprague-Dawley rats to a 50-Hertz, 100-microTesla magnetic field for 27 weeks facilitates mammary tumorigenesis in the 7,12-dimethylbenz[a]-anthracene model of breast cancer.
Thun-Battersby S; Mevissen M; Löscher W
Cancer Res; 1999 Aug; 59(15):3627-33. PubMed ID: 10446973
[TBL] [Abstract][Full Text] [Related]
43. Chemoprevention of mammary cancer by diallyl selenide, a novel organoselenium compound.
el-Bayoumy K; Chae YH; Upadhyaya P; Ip C
Anticancer Res; 1996; 16(5A):2911-5. PubMed ID: 8917406
[TBL] [Abstract][Full Text] [Related]
44. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
[TBL] [Abstract][Full Text] [Related]
45. Diets containing whey proteins or soy protein isolate protect against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats.
Hakkak R; Korourian S; Shelnutt SR; Lensing S; Ronis MJ; Badger TM
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):113-7. PubMed ID: 10667471
[TBL] [Abstract][Full Text] [Related]
46. Biotransformation and biological activity of N-(4-hydroxyphenyl)retinamide derivatives in rodents.
Swanson BN; Newton DL; Roller PP; Sporn MB
J Pharmacol Exp Ther; 1981 Dec; 219(3):632-7. PubMed ID: 6170750
[TBL] [Abstract][Full Text] [Related]
47. Putative metabolites derived from dietary combinations of calcium glucarate and N-(4-hydroxyphenyl)retinamide act synergistically to inhibit the induction of rat mammary tumors by 7,12-dimethylbenz[a]anthracene.
Abou-Issa HM; Duruibe VA; Minton JP; Larroya S; Dwivedi C; Webb TE
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4181-4. PubMed ID: 2967969
[TBL] [Abstract][Full Text] [Related]
48. The peptidomimetic, 1-adamantyl-substituted, and flex-het classes of retinoid-derived molecules: structure-activity relationships and retinoid receptor-independent anticancer activities.
Dawson MI; Fontana JA
Mini Rev Med Chem; 2010 Jun; 10(6):455-91. PubMed ID: 20370709
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of chemopreventive agents in mouse mammary gland organ culture (MMOC) model: a comprehensive review.
Mehta RG; Naithani R; Huma L; Hawthorne M; Moriarty RM; McCormick DL; Steele VE; Kopelovich L
Curr Med Chem; 2008; 15(27):2785-825. PubMed ID: 18991637
[TBL] [Abstract][Full Text] [Related]
50. Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis.
Kocdor H; Kocdor MA; Canda T; Gurel D; Cehreli R; Yilmaz O; Alakavuklar M; Guner G
Clin Transl Oncol; 2009 Apr; 11(4):243-9. PubMed ID: 19380302
[TBL] [Abstract][Full Text] [Related]
51. Chemotherapeutic evaluation of glucarate and N-(4-hydroxyphenyl)retinamide alone and in combination in the rat mammary tumor model.
Abou-Issa H; Webb TE; Minton JP; Moeschberger M
J Natl Cancer Inst; 1989 Dec; 81(23):1820-3. PubMed ID: 2531231
[TBL] [Abstract][Full Text] [Related]
52. Chemopreventive agents induce a senescence-like phenotype in rat mammary tumours.
Christov KT; Shilkaitis AL; Kim ES; Steele VE; Lubet RA
Eur J Cancer; 2003 Jan; 39(2):230-9. PubMed ID: 12509956
[TBL] [Abstract][Full Text] [Related]
53. An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
Weiss KL; Alshafie G; Chapman JS; Mershon SM; Abou-Issa H; Clagett-Dame M; Curley RW
Bioorg Med Chem Lett; 2001 Jun; 11(12):1583-6. PubMed ID: 11412986
[TBL] [Abstract][Full Text] [Related]
54. Conformationally defined retinoic acid analogues. 5. Large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(3',4'-dihydro-1'(2'H)-naphthalen-1'-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid (9cUAB30).
Atigadda VR; Vines KK; Grubbs CJ; Hill DL; Beenken SL; Bland KI; Brouillette WJ; Muccio DD
J Med Chem; 2003 Aug; 46(17):3766-9. PubMed ID: 12904083
[TBL] [Abstract][Full Text] [Related]
55. Microemulsion for Prolonged Release of Fenretinide in the Mammary Tissue and Prevention of Breast Cancer Development.
Salata GC; Malagó ID; Carvalho Dartora VFM; Marçal Pessoa AF; Fantini MCA; Costa SKP; Machado-Neto JA; Lopes LB
Mol Pharm; 2021 Sep; 18(9):3401-3417. PubMed ID: 34482696
[TBL] [Abstract][Full Text] [Related]
56. Distinguishing effects on tumor multiplicity and growth rate in chemoprevention experiments.
Dunson DB; Dinse GE
Biometrics; 2000 Dec; 56(4):1068-75. PubMed ID: 11129462
[TBL] [Abstract][Full Text] [Related]
57. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma.
Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
Invest New Drugs; 1990 Aug; 8(3):317-9. PubMed ID: 2148744
[TBL] [Abstract][Full Text] [Related]
58. Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system.
Zujewski J; Vaughn-Cooke A; Flanders KC; Eckhaus MA; Lubet RA; Wakefield LM
Breast Cancer Res; 2001; 3(1):66-75. PubMed ID: 11250748
[TBL] [Abstract][Full Text] [Related]
59. Fenretinide and cancer prevention.
Torrisi R; Decensi A
Curr Oncol Rep; 2000 May; 2(3):263-70. PubMed ID: 11122852
[TBL] [Abstract][Full Text] [Related]
60. Menthol-beta-D-glucuronide: a potential prodrug for treatment of the irritable bowel syndrome.
Nolen HW; Friend DR
Pharm Res; 1994 Dec; 11(12):1707-11. PubMed ID: 7899232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
